scispace - formally typeset
J

Jinqiang Wang

Researcher at University of California, Los Angeles

Publications -  84
Citations -  8114

Jinqiang Wang is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Insulin & Drug delivery. The author has an hindex of 34, co-authored 69 publications receiving 5089 citations. Previous affiliations of Jinqiang Wang include University of North Carolina at Chapel Hill & Zhejiang University.

Papers
More filters
Journal ArticleDOI

The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment

TL;DR: The micelle's blood circulation time and tumor accumulation increased with the increase in their diameters, with optimal diameter range of 100 to 160 nm, but the much higher tumor accumulation of the large micelles did not result in significantly improved therapeutic efficacy, because the large mouselles had poorer tumor penetration than the small ones.
Journal ArticleDOI

Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery.

TL;DR: The concept directly using drugs as part of a carrier is applicable to fabricating other highly efficient nanocarriers with a substantially reduced use of inert carrier materials and increased drug loading content without premature burst release.
Journal ArticleDOI

Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species.

TL;DR: Tumor site-specific conversion of ROS generation induced by released cisplatin and Fe2+/Fe3+ from iron-oxide nanocarriers with cisPlatin(IV) prodrugs for enhanced anticancer activity but minimized systemic toxicity is demonstrated.
Journal ArticleDOI

Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy

TL;DR: The conjugate showed a potent antitumour activity in mouse models that led to the eradication of small solid tumours and regression of large established tumours with clinically relevant sizes, and significantly extended the survival of orthotopic pancreatic tumour-bearing mice compared to that with the first-line chemotherapeutic drug gemcitabine.